A Pilot Trial of TKI 258 (Dovitinib) in Von Hippel-Lindau Syndrome
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2017
At a glance
- Drugs Dovitinib (Primary)
- Indications Haemangioblastoma; Von Hippel-Lindau disease
- Focus Adverse reactions
- 26 Dec 2015 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
- 23 Mar 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016, as reported by ClinicalTrials.gov.
- 01 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.